Giotrif for Advanced Non Small Cell Lung Cancer - Details


( Last Updated : July 25, 2014)
Generic Name:
Afatinib
Project Status:
Complete
Therapeutic Area:
Advanced or Metastatic Non-Small Cell Lung Cancer
Manufacturer:
Boehringer Ingelheim Canada Ltd.
Brand Name:
Giotrif
Project Line:
Reimbursement Review
Project Number:
PC0032-000
NOC Date:

Details


Strength:
20mg, 30mg, and 40mg tablets
Tumour Type:
Lung
Indications:
Advanced Non Small Cell Lung Cancer
Funding Request:
For the first line treatment of EGFR Mutation Positive, Advanced Non-Small Cell Lung Cancer patients
Review Status:
Complete
Pre Noc Submission:
Yes
Sponsor:
Boehringer Ingelheim Canada Ltd.
Submission Date:
Submission Deemed Complete:
Prioritization Requested:
Not Requested
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Clarification:
A delay in the receipt of Category 2 Part 2 requirements has impacted the review timeline.
Recommendation Type:
Reimburse
Clarification:
A delay in the receipt of Category 2 Part 2 requirements has impacted the review timeline.
Funding Request:
For the first line treatment of EGFR Mutation Positive, Advanced Non-Small Cell Lung Cancer patients
pERC Meeting:
Final Recommendation Issued:

Files

‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.